scholarly journals Linear lichen planus: two case reports

Author(s):  
Gülhan Gürel
Keyword(s):  
2018 ◽  
Vol 5 (1) ◽  
pp. 19-22
Author(s):  
Tejavathi Nagaraj ◽  
C. K. Sumana ◽  
Arundhati Biswas ◽  
Haritma Nigam

2020 ◽  
Vol 26 (2) ◽  
pp. 14
Author(s):  
Maroua Garma ◽  
Wafa Hasni ◽  
Bechir Annabi ◽  
Badreddine Sriha ◽  
Souha Boudegga ◽  
...  

Introduction: Lichen planus is an inflammatory mucocutaneous dermatosis involving skin, appendages and mucosa. Oral mucosa is the most commonly involved in all its sites, rarely the lips especially when isolated. The aim was to conduct a literature review about isolated lichen planus of the lips and reporting two case reports of this lesion in order to highlight epidemiologic, clinical and histological features and therapeutic modalities of this lesion. Observations: Case report 1: a 34-year-old diabetic male patient consulted for an erosive, crusted and hemorrhagic cheilitis of the lower lip. Clinical and histological examination led to the diagnosis of isolated lichen planus of the lips. Case report 2: a 33-year-old female patient was referred from dermatology department for biopsy of chronic cheilitis of the lower lip. Clinical and histological examination confirmed the diagnosis of isolated lichen planus of the lips. Discussion: The review based on 34 case reports of isolated lichen planus of the lips, in addition to literature data confirmed that it is a benign rare lesion affecting mostly male patients having middle age with preponderance of the lower lip, its erosive form is the most frequent and it presents a favorable healing with topical treatment particularly corticosteroids.


2012 ◽  
Vol 16 (4) ◽  
pp. 221-229 ◽  
Author(s):  
Michael Samycia ◽  
Andrew N. Lin

Background: Topical calcineurin inhibitors have been studied in many skin disorders, including lichen planus. Objective: To evaluate published reports of the use of topical calcineurin inhibitors in lichen planus. Methods: We searched PubMed, Ovid/Cochrane, and Embase using the keywords “tacrolimus,” “pimecrolimus,” “topical calcineurin inhibitors,” and “lichen planus.” Results: We examined 5 double-blind studies, 1 investigator-blinded study, 10 open prospective studies, 6 retrospective studies, and 28 case reports evaluating tacrolimus or pimecrolimus for oral, vulvovaginal, and cutaneous lichen planus. Conclusions: Strong evidence (double-blind and open studies) supports the use of topical tacrolimus ointment in oral lichen planus, with efficacy at least equal to topical clobetasol propionate 0.05% ointment. Treatment of oral lichen planus with topical tacrolimus ointment can result in demonstrable blood tacrolimus levels, but without clinically significant adverse events. Strong evidence (double-blind and open studies) supports the use of topical pimecrolimus 1% cream in oral lichen planus, with efficacy equal to that of topical triamcinolone acetonide 0.1% paste. For vulvovaginal lichen planus, pimecrolimus was superior to placebo in one double-blind study, and tacrolimus was effective in open studies. Only case reports support the efficacy of topical calcineurin inhibitors in cutaneous lichen planus.


2017 ◽  
Vol 9 (3) ◽  
pp. 217-224 ◽  
Author(s):  
Woranit Onprasert ◽  
Kumutnart Chanprapaph

Lichen planus pemphigoides (LPP) is a rare autoimmune bullous dermatosis. The clinical presentation of LPP may mimic bullous pemphigoid making the diagnosis difficult. A thorough clinical, histopathological, and immunological evaluation is essential for the diagnosis of LPP. The etiology is largely idiopathic; however, there are several case reports of drug-induced LPP. We report an 81-year-old Thai woman with underlying hypertension and type 2 diabetes mellitus who presented with a 4-week history of multiple tense bullae initially on the hands and feet that subsequently expanded to the trunk and face. Enalapril was commenced to control hypertension. The histopathology and direct immunofluorescence were compatible with LPP. Circulating anti-basement antibodies BP180 was also positive. The patient was treated with topical corticosteroid with a modest effect. Enalapril was discontinued and complete resolution of LPP occurred within 12 weeks. There was no recurrence after a 1-year follow-up period. To the best of our knowledge, we present the first case of enalapril-induced LPP. Early recognition and prompt discontinuation of the culprit drug allow resolution of the disease. Medication given for LPP alone, without cessation of the offending drug, may not change the course of this condition.


1998 ◽  
Vol 23 (3) ◽  
pp. 132-135 ◽  
Author(s):  
SWALE ◽  
BLACK ◽  
BHOGAL
Keyword(s):  

2021 ◽  
Vol 7 (4) ◽  
Author(s):  
Thais Pincelli ◽  
Leila Tolaymat ◽  
Jason Sluzevich ◽  
Alison Bruce

Context: Mucosal lichen planus is a chronic inflammatory debilitating condition that commonly affects the oral mucosa, but other sites such as the genital and ocular mucosae, esophagus and ear canal may also be involved, with risk of scarring and functional compromise. Spontaneous remission is rare and the condition tends to be recalcitrant to therapy, which makes management challenging. Topical therapies are often ineffective in severe cases and official treatment guidelines including systemic agents and procedural interventions are currently not available. Methods: We performed a literature review on current systemic therapies for mucosal lichen planus using PubMed, MEDLINE and Cochrane databases, with 74 publications identified including retrospective and prospective studies, case reports, and clinical trials. Therapies reviewed included biologics, immunosuppressive therapies, immunomodulating and anti-inflammatory drugs, vitamin A derivatives, devices and interventional therapies, and non-prescription drugs. Results: Reported treatments were classified into the following categories: biologics, anti-metabolic immunosuppressives, direct anti-T cell agents, other immunodulatory agents, antibiotics, retinoids, and procedure based interventions. Most studies on mucosal lichen planus are descriptive in nature and demonstrate low levels of evidence. Randomized controlled trials are lacking, which makes it difficult to directly compare different grading scales and outcome. Conclusions: The authors suggest clinical criteria for initiation of therapy in mucosal lichen planus, such as severe disease, lack of response to topical therapy, mucous membranes involvement and involvement of organs at risk of non-function. The authors also propose a stepwise treatment algorithm based on data from this review and their personal experience in an academic tertiary referral center.


2018 ◽  
Vol 28 (3) ◽  
pp. 391-392 ◽  
Author(s):  
Tannvir Desroche ◽  
Sandra Moawad ◽  
Jean-François Cuny ◽  
Bérangère Lerondeau ◽  
Etienne Simon ◽  
...  

2021 ◽  
Vol 10 (4) ◽  
pp. 1-7
Author(s):  
Sadeq A. Al-Maweri ◽  
◽  
Rawan Alanazi ◽  
Mohammed Nasser Alhajj ◽  
Ammar Daer ◽  
...  

Background: Oral lichen planus (OLP) is a chronic inflam-matory disorder with a potential of malignant transformation. Despite the extensive research on the topic, the management of OLP is still quite challenging, with no definitive cure. Objective: The present systematic review assessed the efficacy of topical hyaluronic acid in the management of OLP. Material and Methods: A comprehensive search of PubMed, Scopus, Web of Science and Google Scholar was carried out by two independent investigators. All randomized clinical trials that compared the efficacy of hyaluronic acid with other interventions and/or placebo in the management of OLP and fulfilled the following criteria were included: 1) OLP diagnosis was confirmed clinically and histopathologically, 2) the study included systemically healthy patients aged 15 years and older, 3) a minimum sample size of 10, and 4) reporting the main outcomes including pain, erythema, and ulcer size. Case reports, case series, reviews, animal studies, uncontrolled trials were excluded. Results: Four clinical trials involving 234 patients were included. Two studies compared hyaluronic acid with a topical corticosteroid, and two studies compared it with placebo. Only one of the four included studies was at low risk of bias. Overall, topical hyaluronic acid showed good efficacy in alleviating the signs and symptoms of OLP. Two studies found hyaluronic acid significantly more effective in reducing pain and improving clinical signs of OLP compared to placebo. Compared to topical corticosteroids, one study reported comparable results; and one study found hyaluronic acid to be superior to triamcinolone in reducing pain but inferior to triamcinolone in improving the healing time. Conclusion: The limited available evidence suggests that hyaluronic acid may have some benefits in the management of OLP. Further well-designed studies with adequate follow-up periods are highly recommended.


2010 ◽  
Vol 25 (2) ◽  
pp. 208-212
Author(s):  
Maiara de Moraes ◽  
Felipe Rodrigues de Matos ◽  
Joabe dos Santos Pereira ◽  
Ana Myriam Costa de Medeiros ◽  
Éricka Janine Dantas da Silveira

Sign in / Sign up

Export Citation Format

Share Document